admin

August 28, 2023

Tan Tock Seng Hospital (Singapore) site visit by CEO
2nd August 2023

OBM’s CEO was invited by Dr. Rupesh Agrawal – Deputy Research Head at Singapore’s Tan Tock Seng Hospital (TTSH) to tour the Ophthalmology department research facilities […]
August 28, 2023

ACRO Biomedicals & Krisan Biotech site visit – Tainan, Taiwan
25th July 2023

OBM’s CEO & CSO held meetings with the company’s key business and scientific partners –ACRO Biomedical’s & Krisan Biotech CEO’s (D.J. Hsieh & Jamie Hung respectively) […]
July 30, 2023

OBM presented at BioAsia, Taipei, Taiwan
26th-30th July 2023

Bio-Asia Taiwan is Asia’s largest biotech conference and networking event. OBM was invited by the Australian Government Trade Arm – Austrade to present at this event. OBM […]
July 1, 2023

Professor Robyn Guymer AM appointed to OBM Scientific Board
1st July 2023

We are delighted to welcome Robyn to the OBM Scientific Board. She brings significant experience and currency to the company. Background profile follows: Professor Robyn Guymer […]
May 24, 2023

AusMedtech conference Adelaide;
24th – 25th May 2023

OBM was represented by its CEO & CSO. This was OBM’s first formal representation at an industry conference which included valuable one-on-one private meetings with industry […]
February 22, 2022

Melbourne, Australia;
22 February 2022 – Research Data Which Covers OBM’s OBM-1701 for the Treatment of wet-AMD Has Been Published on a Prominent Peer-reviewed Journal

Oculus Biomed Limited (“OBM”) is pleased to announce that the research data which covers OBM’s OBM-1701, its leading drug candidate for the treatment of wet-AMD, has […]
October 5, 2021

Melbourne, Australia;
05 October 2021 – OBM Enters R&D Agreement with Centre for Eye Research Australia (“CERA”)

Oculus Biomed Limited (“OBM”) is pleased to announce that it has entered an Agreement with Centre for Eye Research Australia (“CERA”), in Melbourne, Victoria State, Australia. […]
June 11, 2021

Melbourne, Australia;
11 June 2021 – Key Chinese Patent covering OBM-1701 Granted

Oculus Biomed Limited (“OBM”) is pleased to announce the grant of the Chinese Patent which covers the OBM-1701, OBM’s leading novel drug candidate for treating wet-type […]
June 2, 2021

Melbourne, Australia;
2 June 2021 – Key EU Patent covering OBM-1701 Granted

Oculus Biomed Limited (“OBM”) is pleased to announce the European patent application which covers the OBM-1701, OBM’s leading novel drug candidate for treating wet-type age-related macular […]